Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
3
Feb |
Alzheimer’s-Related Protein In Brains Of Healthy Adults May Shed Light On Earliest Signs Of DiseaseCategory: Alzheimer's / Dementia | Leave a Comment |
Researchers from the Center for Vital Longevity at the University of Texas at Dallas and UT Southwestern Medical Center have completed a large-scale neuroimaging study of healthy adults from age 30 to 90 that measured beta-amyloid protein - a substance whose toxic buildup in the brain is a diagnostic marker for Alzheimer’s disease…
|
13
Jan |
Advance Toward An Imaging Agent For Diagnosing Alzheimer’s DiseaseCategory: Alzheimer's / Dementia | Leave a Comment |
Scientists are reporting development and initial laboratory tests of an imaging agent that shows promise for detecting the tell-tale signs of Alzheimer’s disease (AD) in the brain - signs that now can’t confirm a diagnosis until after patients have died. Their report appears in the journal ACS Medicinal Chemistry Letters…
|
30
Sep |
Pregnancy Protein Detected In Older People Destined For Alzheimer’s DiseaseCategory: Alzheimer's / Dementia | Leave a Comment |
In an advance toward a much-needed early diagnostic test for Alzheimer’s disease (AD), scientists have discovered that older women destined to develop AD have high blood levels of a protein linked to pregnancy years before showing symptoms. Their report appears in ACS’ Journal of Proteome Research…
|
4
Aug |
Researchers Develop Reliable, Accurate Blood Test For Alzheimer’sCategory: Alzheimer's / Dementia | Leave a Comment |
Scientists from Durin Technologies, Inc., and the University of Medicine and Dentistry of New Jersey (UMDNJ)-School of Osteopathic Medicine have developed a blood test that uses human protein microarrays to detect the presence of specific antibodies in the blood that can be used to diagnose Alzheimer’s disease with unprecedented accuracy…
|
15
Jun |
European Scientists Develop Several Methods For Early Diagnosis Of Alzheimer’s DiseaseCategory: Alzheimer's / Dementia | Leave a Comment |
PredictAD is an EU-funded research project that develops objective and efficient methods for enabling earlier diagnosis of Alzheimer’s disease. Diagnosis requires a holistic view of the patient combining information from several sources, such as, clinical tests, imaging and blood samples…
|
12
Feb |
Preliminary New Blood Test To Detect Alzheimer’s Disease UncoveredCategory: Alzheimer's / Dementia | Leave a Comment |
UT Southwestern Medical Center scientists have helped develop a novel technology to diagnose Alzheimer’s disease from blood samples long before symptoms appear…
|
26
Jan |
Shunt Makes Dementia Patients Faster And SmarterCategory: Alzheimer's / Dementia | Leave a Comment |
Researchers from the University of Gothenburg and Sahlgrenska University Hospital are the first in the world to show that an operation can help patients with dementia caused by white matter changes and hydrocephalus. Presented in the American Journal of Neurosurgery, the results are based on the world’s first study to demonstrate the effects of a shunt operation using a placebo control…
|
14
Dec |
Alzheimer Patients Brain Tracked By PET Scanner During Disease And After DeathCategory: Alzheimer's / Dementia | Leave a Comment |
For the first time the brain of a patient with Alzheimer’s disease who displayed detectable amyloids with a PET scanner was regularly scanned as his disease progressed, and then his brain was analyzed after he died, researchers from the Karolinska Institutet, Sweden, reveal in the medical journal Brain…
|
13
Dec |
Simple Small Molecules Could Untangle Alzheimer’s DiseaseCategory: Alzheimer's / Dementia | Leave a Comment |
New molecular tools developed at the University of Michigan show promise for “cleansing” the brain of amyloid plaques, implicated in Alzheimer’s disease. A hallmark of Alzheimer’s disease - a neurodegenerative disease with no cure - is the aggregation of protein-like bits known as amyloid-beta peptides into clumps in the brain called plaques…
|
2
Dec |
GE Healthcare Announces Major Research Collaboration To Identify Diagnostic Biosignatures In Early Alzheimer’s Disease DetectionCategory: Alzheimer's / Dementia | Leave a Comment |
GE Healthcare announced a research agreement to collaborate with Janssen Pharmaceutica NV, L.L.C. (Janssen) to identify a biosignature related to Alzheimer’s disease. This research effort will combine expertise in data integration, informatics, genomics and imaging. Its goal will be to find a biosignature that may enable the detection of Alzheimer’s disease before the onset of clinical symptoms…